NCT06722222 Gao's Triple Eversion Carotid Endarterectomy
| NCT ID | NCT06722222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| Condition | Carotid Artery Stenosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 11 participants |
| Start Date | 2021-09-17 |
| Primary Completion | 2031-09-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 11 participants in total. It began in 2021-09-17 with a primary completion date of 2031-09-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Carotid endarterectomy (CEA), an important surgical approach for managing carotid plaque, has evolved over more than 70 years but still cannot be applied to all tandem carotid lesions (TCLs) because of the wide range of these lesions. Herein, the investigators introduce an innovative CEA, Gao's triple eversion CEA (GTE-CEA), for the treatment of TCLs.
Eligibility Criteria
Inclusion Criteria: * Meet the diagnostic criteria for TCL stenosis. * Above 70% asymptomatic CCA and ICA stenosis or \> 50% symptomatic CAS confirmed by DSA or CTA before surgery Exclusion Criteria: * Did not meet the diagnostic criteria for CAS * Asymptomatic CAS \< 50% (as confirmed by DSA or CTA before surgery) * With stenosis at the opening of the CCA.
Contact & Investigator
Zhiwei Gao, Dr.
STUDY DIRECTOR
Second Affiliated Hospital, Zhejiang University, School of Medicine
Frequently Asked Questions
Who can join the NCT06722222 clinical trial?
This trial is open to participants of all sexes, studying Carotid Artery Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06722222 currently recruiting?
Yes, NCT06722222 is actively recruiting participants. Contact the research team at 2324050@zju.edu.cn for enrollment information.
Where is the NCT06722222 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06722222 clinical trial?
NCT06722222 is sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. The principal investigator is Zhiwei Gao, Dr. at Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 11 participants.